TY  - JOUR
AU  - Perez-Calahorra, Sofia
AU  - Laclaustra, Martin
AU  - Marco-Benedi, Victoria
AU  - Lamiquiz-Moneo, Itziar
AU  - Pedro-Botet, Juan
AU  - Plana, Nuria
AU  - Sanchez-Hernandez, Rosa M
AU  - Amor, Antonio J
AU  - Almagro, Fátima
AU  - Fuentes, Francisco
AU  - Suarez-Tembra, Manuel
AU  - Civeira, Fernando
PY  - 2019
DO  - 10.1016/j.atherosclerosis.2019.02.003
UR  - http://hdl.handle.net/10668/13654
T2  - Atherosclerosis
AB  - The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new...
LA  - en
PB  - Elsevier
KW  - Cardiovascular disease
KW  - Familial hypercholesterolemia
KW  - Lipid-lowering
KW  - Statins
KW  - Adult
KW  - Aged
KW  - Cardiovascular diseases
KW  - Female
KW  - Humans
KW  - Hyperlipoproteinemia type II
KW  - Hypolipidemic agents
KW  - Male
KW  - Middle aged
KW  - Prevalence
KW  - Retrospective studies
KW  - Treatment outcome
TI  - Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
TY  - research article
VL  - 284
ER  -